CCA
STSA

Catalyst Capital Advisors’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Catalyst Capital Advisors’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-333
Closed -$5K – 440
2019
Q3 		$5K Buy
+333
New +$5.17K ﹤0.01% 405

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's STSA Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2019, closing a stake of 333 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in STSA in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 32 funds tracked by Wall St. Rank hold STSA as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 333 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $5K in Q3 2019.
  • 32 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.